Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H22N2.2C4H4O4 |
| Molecular Weight | 522.5464 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 2 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.CN1CCC(CC1)=C2C3=CC=CC=C3CCC4=C2N=CC=C4
InChI
InChIKey=SGHXFFAHXTZRQM-SPIKMXEPSA-N
InChI=1S/C20H22N2.2C4H4O4/c1-22-13-10-16(11-14-22)19-18-7-3-2-5-15(18)8-9-17-6-4-12-21-20(17)19;2*5-3(6)1-2-4(7)8/h2-7,12H,8-11,13-14H2,1H3;2*1-2H,(H,5,6)(H,7,8)/b;2*2-1-
| Molecular Formula | C4H4O4 |
| Molecular Weight | 116.0722 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
| Molecular Formula | C20H22N2 |
| Molecular Weight | 290.4021 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.drugs.com/mtm/optimine.html
Sources: https://www.drugs.com/mtm/optimine.html
Azatadine is an antihistamine, which blocks the effects of the naturally occurring chemical histamine in the body. Azatadine is used to treat sneezing; runny nose; itching, watery eyes; hives; rashes; and other symptoms of allergies and the common cold. The antihistamines antagonize those pharmacological effects of histamine, which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue injury response involving histamine release.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL231 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2568212 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
Sources: https://www.drugs.com/mtm/optimine.html |
Palliative | OPTIMINE Approved UseAzatadine is used to treat sneezing; runny nose; itching, watery eyes; hives; rashes; itching; and other symptoms of allergies and the common cold. Launch Date1977 |
||
Sources: https://www.drugs.com/mtm/optimine.html |
Palliative | OPTIMINE Approved UseAzatadine is used to treat sneezing; runny nose; itching, watery eyes; hives; rashes; itching; and other symptoms of allergies and the common cold. Launch Date1977 |
||
Sources: https://www.drugs.com/mtm/optimine.html |
Palliative | OPTIMINE Approved UseAzatadine is used to treat sneezing; runny nose; itching, watery eyes; hives; rashes; itching; and other symptoms of allergies and the common cold. Launch Date1977 |
||
Sources: https://www.drugs.com/mtm/optimine.html |
Palliative | OPTIMINE Approved UseAzatadine is used to treat sneezing; runny nose; itching, watery eyes; hives; rashes; itching; and other symptoms of allergies and the common cold. Launch Date1977 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21737359/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
AZATADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
20.5 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21737359/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
AZATADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
10.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21737359/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
AZATADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/11996015/ |
yes |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| yes |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010-12 |
|
| Application of dummy molecularly imprinted solid-phase extraction in the analysis of cyproheptadine in bovine urine. | 2009-05 |
|
| Syntheses of molecularly imprinted polymers: Molecular recognition of cyproheptadine using original print molecules and azatadine as dummy templates. | 2009-01-12 |
|
| Antihistamines in the treatment of dermatitis. | 2005-06-01 |
|
| The use of antiserotonin drugs in the nucleoreticular vestibular syndrome: preliminary observations. | 2004 |
|
| Quantitation of antihistamines in pharmaceutical preparations by liquid chromatography with a micellar mobile phase of sodium dodecyl sulfate and pentanol. | 2002-01-05 |
|
| Antiallergic anti-inflammatory effects of H1-antihistamines in humans. | 2002 |
|
| Chromatographic analysis of phenethylamine-antihistamine combinations using C8, C18 or cyano columns and micellar sodium dodecyl sulfate-pentanol mixtures. | 2001-04 |
|
| Antiallergic effects of H1-receptor antagonists. | 2000 |
|
| Fungal biotransformation of the antihistamine azatadine by Cunninghamella elegans. | 1996-09 |
|
| The effect of antihistamines on the immediate allergic response: a comparative review. | 1993-06 |
|
| Comparative effects of loratadine and azatadine in the treatment of seasonal allergic rhinitis. | 1990-12 |
|
| Effects of azatadine, terfenadine, and astemizole on allergen-induced nasal provocation. | 1990-02 |
|
| "In vivo" and "in vitro" evaluation of four antihistamines (astemizole, azatadine, mequitazine, terfenadine). | 1989-03-01 |
|
| Demonstration of inhibition of mediator release from human mast cells by azatadine base. In vivo and in vitro evaluation. | 1986-01-10 |
|
| Peripheral antihistamine and central sedative effects of three H1-receptor antagonists. | 1985 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/mtm/optimine.html
The maximum amount of azatadine that you should take in 1 day is 2 mg. Azatadine can be taken with or without food.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2424773
Azatadine 0.1-10 uM significantly and dose dependently inhibited the release of leukotrienes from lung by 22-71%. Histamine release was also inhibited by azatadine 10 uM.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:47:56 GMT 2025
by
admin
on
Mon Mar 31 17:47:56 GMT 2025
|
| Record UNII |
F3Q391WTX7
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29578
Created by
admin on Mon Mar 31 17:47:56 GMT 2025 , Edited by admin on Mon Mar 31 17:47:56 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
m2164
Created by
admin on Mon Mar 31 17:47:56 GMT 2025 , Edited by admin on Mon Mar 31 17:47:56 GMT 2025
|
PRIMARY | Merck Index | ||
|
DTXSID301027735
Created by
admin on Mon Mar 31 17:47:56 GMT 2025 , Edited by admin on Mon Mar 31 17:47:56 GMT 2025
|
PRIMARY | |||
|
3978-86-7
Created by
admin on Mon Mar 31 17:47:56 GMT 2025 , Edited by admin on Mon Mar 31 17:47:56 GMT 2025
|
PRIMARY | |||
|
DBSALT000973
Created by
admin on Mon Mar 31 17:47:56 GMT 2025 , Edited by admin on Mon Mar 31 17:47:56 GMT 2025
|
PRIMARY | |||
|
CHEMBL946
Created by
admin on Mon Mar 31 17:47:56 GMT 2025 , Edited by admin on Mon Mar 31 17:47:56 GMT 2025
|
PRIMARY | |||
|
223-615-8
Created by
admin on Mon Mar 31 17:47:56 GMT 2025 , Edited by admin on Mon Mar 31 17:47:56 GMT 2025
|
PRIMARY | |||
|
58275
Created by
admin on Mon Mar 31 17:47:56 GMT 2025 , Edited by admin on Mon Mar 31 17:47:56 GMT 2025
|
PRIMARY | RxNorm | ||
|
C61642
Created by
admin on Mon Mar 31 17:47:56 GMT 2025 , Edited by admin on Mon Mar 31 17:47:56 GMT 2025
|
PRIMARY | |||
|
100000084967
Created by
admin on Mon Mar 31 17:47:56 GMT 2025 , Edited by admin on Mon Mar 31 17:47:56 GMT 2025
|
PRIMARY | |||
|
5281066
Created by
admin on Mon Mar 31 17:47:56 GMT 2025 , Edited by admin on Mon Mar 31 17:47:56 GMT 2025
|
PRIMARY | |||
|
2947
Created by
admin on Mon Mar 31 17:47:56 GMT 2025 , Edited by admin on Mon Mar 31 17:47:56 GMT 2025
|
PRIMARY | |||
|
SUB00640MIG
Created by
admin on Mon Mar 31 17:47:56 GMT 2025 , Edited by admin on Mon Mar 31 17:47:56 GMT 2025
|
PRIMARY | |||
|
F3Q391WTX7
Created by
admin on Mon Mar 31 17:47:56 GMT 2025 , Edited by admin on Mon Mar 31 17:47:56 GMT 2025
|
PRIMARY | |||
|
759874
Created by
admin on Mon Mar 31 17:47:56 GMT 2025 , Edited by admin on Mon Mar 31 17:47:56 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |